Pair Name	Astragaloside IV, Carboplatin
Disease Info	[ICD-11: 2C82]	Prostate cancer		Investigative
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Expression	NFKB1	hsa4790
	Up-regulation	Phosphorylation	NFKBIA	hsa4792
	Up-regulation	Cleavage	PARP1	hsa142
	Down-regulation	Phosphorylation	RELA	hsa5970
In Vitro Model	LNCaP	Prostate carcinoma	Homo sapiens (Human)	CVCL_0395
	PC-3	Prostate carcinoma	Homo sapiens (Human)	CVCL_0035
In Vivo Model	AgIV synergized with carboplatin to suppress tumor xenograft growth of PC-3 cells, and decreased pAKT and p-p65 levels in vivo.
Result	Our results suggested that AgIV enhanced carboplatin sensitivity in prostate cancer cell lines by suppressing AKT/NF-κB signaling, thus suppressed epithelial-mesenchymal transition induced by carboplatin. Our findings provided a new mechanism for AgIV in overcoming drug resistance of platinum-based chemotherapy and suggested a potential combination therapy of AgIV and carboplatin in prostate cancer.